CNBC interviews Alkermes CEO about antidepressant comeback

Third time is apparently the charm for Alkermes antidepressant ALKS 5461. This drug is targeted at depression patients who do not receive adequate relief from more traditional antidepressants, such as SSRIs. The first two phase III studies led to lackluster results, but this third study met its primary endpoint, causing the Alkermes stock to leap over 40% when the news broke. 

In this video, Jim Cramer interviews Alkermes CEO Richard Pops about ALKS 5461, as well as Vivitrol, a drug for opioid dependence.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.